IMP-1088 |
Catalog No.GC40101
One-Click Copy Product Info
|
IMP-1088 is a picomolar dual inhibitor of the human N-myristoyltransferases NMT1 with IC50 value of 0.24nM and NMT2 ith IC50 value < 1nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2059148-82-0
Sample solution is provided at 25 µL, 10mM.
IMP-1088 is a picomolar dual inhibitor of the human N-myristoyltransferases NMT1 with IC50 value of 0.24nM and NMT2 ith IC50 value < 1nM.[1]. IMP-1088 exhibits broad-spectrum antiviral potential, targeting mammarenaviruses, respiratory rhinoviruses, and malaria parasites[2][3].
In vitro, IMP-1088 exposure (1mM to 0.1pM) on breast cancer MDA-MB-231 cells and cervical cancer HeLa cells for 24, 48 or 72h affected proliferation of MDA-MB-231 and HELA cells only after 48 and 72h and in a concentration-dependent manner. IMP-1088 exposure (1μM) for 18h significantly inhibited N-myristoylation of the majority of NMT substrate proteins identified but did not reduce protein synthesis or alter cell cycles[4]. IMP-1088 (1μM) treated HEK293T cells transfected with plasmids expressing lymphocytic choriomeningitis virus polymerase proteins and nucleoprotein for 24h targeting Z protein myristoylation impairs virus assembly and budding without affecting Z-mediated inhibition of viral ribonucleoprotein (vRNP) activity[5]. IMP-1088 (0.001-100μM) treated HeLa cells infected with Vaccinia virus (VACV) for 24h caused a reduction of > 50% in both virus yield and viral spread at approximately 100nM, without cellular toxicity observed in the presence of up to 10μM IMP-1088[6].
References:
[1] Mousnier A, Bell A S, Swieboda D P, et al. Fragment-derived inhibitors of human N-myristoyltransferase block capsid assembly and replication of the common cold virus. Nat Chem. 2018 Jun;10(6):599-606.
[2] Agoni C, Salifu E Y, Enslin G, Kwofie S K, Soliman M E. Dual-Inhibition of Human N-Myristoyltransferase Subtypes Halts Common Cold Pathogenesis: Atomistic Perspectives from the Case of IMP-1088. Chem Biodivers. 2022 Feb;19(2):e2021007.
[3] Mendez A, Bolling C, Taylor S, et al. Structure of Plasmodium vivax N-myristoyltransferase with inhibitor IMP-1088: exploring an NMT inhibitor for antimalarial therapy. Acta Crystallogr F Struct Biol Commun. 2025 Jan 1;81(Pt 1):1-10.
[4] Kallemeijn W W, Lueg G A, Faronato M, et al. Validation and Invalidation of Chemical Probes for the Human N-myristoyltransferases. Cell Chem Biol. 2019 Jun 20;26(6):892-900.e4.
[5] Witwit H, de la Torre J C. Mammarenavirus Z Protein Myristoylation and Oligomerization Are Not Required for Its Dose-Dependent Inhibitory Effect on vRNP Activity. Biochem (Basel). 2025 Jun;5(2):10.
[6] Priyamvada L, Kallemeijn W W, Faronato M, et al. Inhibition of vaccinia virus L1 N-myristoylation by the host N-myristoyltransferase inhibitor IMP-1088 generates non-infectious virions defective in cell entry. PLoS Pathog. 2022 Oct 10;18(10):e1010662.
| Cell experiment [1]: | |
Cell lines | Breast cancer MDA-MB-231 cells and cervical cancer HeLa cells |
Preparation Method | MDA-MB-231 cells and cervical cancer HeLa cells were Exposure to IMP-1088 (1μM) for 18h. |
Reaction Conditions | 1μM; 18h |
Applications | Exposure to IMP-1088 (1μM) for 18h significantly inhibited N-myristoylation of the majority of NMT substrate proteins identified but did not reduce protein synthesis or alter cell cycles. |
References: | |
| Cas No. | 2059148-82-0 | SDF | |
| Chemical Name | 5-[3,4-difluoro-2-[2-(1,3,5-trimethyl-1H-pyrazol-4-yl)ethoxy]phenyl]-N,N,1-trimethyl-1H-indazole-3-methanamine | ||
| Canonical SMILES | FC1=C(F)C=CC(C2=CC=C(N(C)N=C3CN(C)C)C3=C2)=C1OCCC4=C(C)N(C)N=C4C | ||
| Formula | C25H29F2N5O | M.Wt | 453.5 |
| Solubility | A solution in methyl acetate | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2051 mL | 11.0254 mL | 22.0507 mL |
| 5 mM | 441 μL | 2.2051 mL | 4.4101 mL |
| 10 mM | 220.5 μL | 1.1025 mL | 2.2051 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solution in methyl acetate
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)